Weight
Weight
Tirzepatide.
A dual GLP-1 / GIP receptor agonist. Slows gastric emptying and lifts satiety signaling — under doctor or clinician guidance, with monthly check-ins.
$349 / month
Includes consultation · vial · syringes · sharps return
Payment is collected before clinical review. GEN displays the total due today at checkout. A prescription is not guaranteed.
ClassEngineered GLP-1/GIP dual agonist
RouteSubcutaneous
Course12 weeks · monthly doctor or clinician check-ins
CompoundC225H348N48O68
Mol. weight4813.5 g/mol
Doctor- or clinician-approvedCompounded to orderThird-party testedCancel anytime
All 50 states
Chain of custody
Who handles your medication, at every step.
PRESCRIBED
Your doctor or clinician
DEA-registered · state-licensed
Issued at consult
COMPOUNDED
503A / 503B partner pharmacy
State-licensed facility
To your prescription
TESTED
Independent lab
Sterility · potency · endotoxin
Before release
RELEASED
Licensed pharmacist
Signs the batch record
Before shipping
Indications
Considered for adults with
- Type 2 diabetes mellitus (FDA-indicated)
- Chronic weight management · BMI ≥ 27 + comorbidity
- Metabolic syndrome, on doctor or clinician judgment
- Pre-diabetes with elevated HbA1c
Counter-indications
Not prescribed when
- ×Personal or family history of medullary thyroid carcinoma
- ×MEN-2 syndrome
- ×Active pancreatitis or biliary disease
- ×Pregnancy, planned pregnancy, or breastfeeding
© 2026 Clark Health Technologies, LLCThis site does not provide medical advice. A licensed doctor or clinician reviews every consultation.Made in the United States